Answer
Dry mouth is classified as uncommon with Spiolto Respimat, although it occurred in approximately 1.3% of patients treated with Spiolto Respimat in long-term 52-week clinical trials.
Sources for this answer
- Spiolto Respimat 2.5 microgram/2.5 microgram, inhalation solutionBoehringer Ingelheim Limited · emc · SmPC §4.8 Undesirable effects · Version 9Document updated
Sources checked